研究称一种药可阻碍艾滋病病毒增殖
作者: 来源:新华网 发布者: 亦云 类别:新闻扫描 日期: 2011-01-16 今日/总浏览: 24/24 |
近日，德国研究人员报告说，他们发现一种进入临床试验阶段的新药可有效阻碍艾滋病病毒在早期感染者体内增殖，并有助于研发其他抗病毒药物。
这种代号为ＶＩＲ－５７６的药物由总部位于德国汉诺威的ＶＩＲＯ制药公司开发。在临床试验中，研究人员对１８名艾滋病病毒感染者连续１０天注射这种药。这是这些感染者首次接受抗逆转录病毒药物治疗，在治疗期间他们不使用其他抗艾滋病药物。结果发现，这些志愿者血液中的艾滋病病毒总量可减少９５％。
参与研究的德国乌尔姆大学医院专家弗兰克·基希霍夫解释说，ＶＩＲ－５７６通过阻止艾滋病病毒附着人体免疫细胞而发挥作用。艾滋病病毒侵袭人体免疫细胞的过程有点像船只靠岸，病毒细胞会抛出“锚”——即融膜肽勾住人体细胞。而ＶＩＲ－５７６可以“抱”住艾滋病病毒抛出的“锚”，阻止它嵌入人体细胞膜，从而使病毒无法入侵细胞。
研究人员说，由于艾滋病病毒与流行性感冒、腮腺炎、乙肝、丙肝病毒以及埃博拉病毒等同属包膜病毒，ＶＩＲ－５７６的疗效表明，或许将来可以利用它研发抵抗上述其他病毒的药物。
研究人员说，虽然临床试验结果非常乐观，并且与抗艾滋病传统药物相比，ＶＩＲ－５７６的副作用较小，但它也存在许多需要改进之处。因为ＶＩＲ－５７６是一种肽，其价格非常昂贵，并且只能通过静脉注射方式给药，使用起来不太方便。这些不足有待深入研究加以解决。
|
|
 |
| 图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构 |
| |
|
|
A study said the proliferation of drug can block the AIDS virus
-------------------------------------------------- ------------------------------
Author: Source: Xinhua Posted by: Yiyun Category: News Scan Date: 2011-01-16 Today / Total View: 24/24
Recently, German researchers report that they found a new drug in clinical trials can effectively prevent HIV infection in vivo in the early proliferation and contribute to development of other antiviral drugs.
The VIR-576, code-named drugs from the headquarters in Hanover, Germany VIRO pharmaceutical company development. In clinical trials, researchers infected 18 HIV injection of the drug for 10 days. This is the first of these infected antiretroviral drug therapy, during which they do not use in the treatment of other anti-AIDS drugs. It was found that the volunteers of the AIDS virus in blood volume can be reduced by 95%.
University of Ulm in Germany participated in the study expert Frank Kirchhoff Hospital explained that, VIR-576 of HIV by preventing the attachment of human immune cells play a role. HIV attacks human immune cells in the process a bit like a ship dock, the virus cell throws "anchor" - that is, human cells finance Peptide hooked. The VIR-576 can "hold" to live with HIV throw the "anchor" to prevent it from embedding human cell membrane, so that the virus can not invade cells.
The researchers said that due to HIV and influenza, mumps, hepatitis B, hepatitis C virus and Ebola virus are both enveloped viruses, VIR-576's efficacy that might in the future can use it to develop drugs against these other viruses .
The researchers said that although the clinical trial results are very optimistic, and compared with traditional medicines to fight AIDS, VIR-576 lower side effects, but it also has many needs to be improved. Because VIR-576 is a peptide, and its price is very expensive and can only be administered by intravenous injection, is not so convenient to use. Depth study of these deficiencies to be addressed.
Of:
Source: Xinhua
Posted by: Yiyun
